Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

Next Previous
Trial Profile

Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gilteritinib (Primary) ; Ziftomenib (Primary) ; Azacitidine; Cytarabine; Daunorubicin; Fludarabine; Granulocyte colony-stimulating factors; Idarubicin; Venetoclax
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Acronyms KOMET-008
  • Sponsors Kura Oncology

Most Recent Events

  • 12 Jan 2026 According to Kura Oncology media release, company expects to present preliminary data from KOMET-008 cohort evaluating combination with gilteritinib in R/R NPM1-m/FLT3-m AML in the second half of 2026.
  • 04 Nov 2025 According to Kura Oncology media release, company announced present preliminary data from the KOMET-008 cohort evaluating ziftomenib in combination with the FLT3 inhibitor gilteritinib in patients with R/R NPM1-m AML in 2026.
  • 10 Jan 2024 Planned initiation date changed from 1 Dec 2023 to 1 Jan 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top